Keywords: Irregular Sleep, Brain Aging, Neurodegeneration, Glymphatic System, Circadian Rhythm, Cognitive Decline, Dementia, Longevity, Epigenetic Clock, Telomere Attrition
Introduction
Sleep is no longer regarded merely as a passive state of rest. Decades of neuroscientific inquiry have established sleep as an active, biologically essential process during which the brain undergoes synaptic consolidation, metabolic waste clearance, immune modulation, and cellular repair. Despite this recognition, global trends continue to demonstrate widespread sleep insufficiency and irregularity, with epidemiological surveys estimating that 30–45% of adults in high-income nations report chronically inadequate or disrupted sleep [1,2].
Historically, research attention focused on sleep duration, the cumulative hours of nightly sleep as the primary metric of sleep health. However, mounting evidence from longitudinal cohorts and experimental neuroscience reveals that sleep regularity, the day-to-day consistency of sleep and wake timing may be an equally, if not more, consequential determinant of brain health and cognitive longevity. The Sleep Regularity Index (SRI), derived from continuous actigraphy, quantifies the probability of an individual being in the same sleep-wake state at any two time points exactly 24 hours apart, and has emerged as a clinically meaningful measure independent of duration [3,4,5].
The neurological consequences of irregular sleep span a spectrum from subtle cognitive impairment to overt neurodegenerative pathology. Irregular sleep-wake patterns are among the earliest manifestations of Alzheimer’s disease (AD) and other dementias, yet they also appear upstream of clinical neurodegeneration, functioning as a mechanistic driver rather than a mere symptom. This bidirectionality renders irregular sleep a critical target for prevention [6].
From a longevity medicine perspective, the brain aging trajectory, quantified by the Brain Age Gap (BAG), the difference between MRI-predicted brain age and chronological age represents a sensitive biomarker of cumulative neurological wear. Positive BAG values (a brain appearing older than its chronological age) correlate with increased mortality risk, faster progression from mild cognitive impairment (MCI) to dementia, and worse functional outcomes across multiple domains. Emerging neuroimaging evidence from cohorts exceeding 25,000 participants consistently demonstrates that suboptimal sleep health predicts 1–3 additional years of brain age acceleration on MRI [7,8].
This review integrates molecular, neuroimaging, epidemiological, and clinical evidence to construct a comprehensive model of how irregular sleep accelerates brain aging. It further explores preventive and therapeutic strategies that may attenuate this trajectory, with relevance for clinicians, researchers, and practitioners in longevity medicine, preventive health, and metabolic wellness.
Defining Sleep Irregularity: Beyond Duration
Dimensions of Sleep Health
Sleep health is a multidimensional construct encompassing duration, regularity, efficiency, timing, satisfaction, and daytime alertness. The RU-SATED model (Regularity, Satisfaction, Alertness, Timing, Efficiency, Duration) proposed by Buysse (2014) explicitly positions regularity as a central pillar of sleep health, distinct from duration. Regulatory irregularity refers to intra-individual variability in sleep onset time, wake time, and total sleep duration across days and weeks [9].
Chronic sleep irregularity manifests across several clinical phenotypes: (i) social jetlag, the discordance between biologically preferred sleep timing on free days versus workdays; (ii) Irregular Sleep-Wake Rhythm Disorder (ISWRD), characterized by a loss of a consolidated sleep-wake cycle with multiple fragmented sleep bouts across 24 hours; and (iii) high sleep variability, defined by standard deviations in nightly sleep duration or timing exceeding one hour. All three phenotypes share a common pathophysiological thread: disruption of the circadian pacemaker in the suprachiasmatic nucleus (SCN) of the hypothalamus [10,11].
The Sleep Regularity index
Phillips et al. developed the Sleep Regularity Index (SRI) as a standardized metric for quantifying sleep consistency using wrist actigraphy. Scores range from 0 (perfectly irregular) to 100 (perfectly regular), with population means typically falling between 60 and 85 in healthy adults. A 2024 dose-response analysis in Japanese adults demonstrated a significant inverse relationship between SRI quartiles and stage-specific Alzheimer’s disease risk, with each decrement in SRI associated with progressively greater odds of preclinical and clinical AD pathology. Crucially, this association persisted after adjustment for sleep duration, underscoring the independent contribution of regularity [5,12].
A systematic review and meta-analysis published in 2025 pooled data from 18 studies and found that higher sleep variability was significantly associated with declines in memory, executive function, processing speed, and verbal fluency in older adults, with effect sizes comparable to those observed with short sleep duration [13].
Mechanistic Pathways: How Irregular Sleep Damages
Circadian Rhythm Disruption and the SCN
The mammalian circadian clock is orchestrated by the SCN, which coordinates peripheral oscillators throughout the brain and body via neurohumoral signals including melatonin, cortisol, and neuropeptide Y. Chronic sleep irregularity desynchronises these central-peripheral relationships, producing a state of internal circadian misalignment analogous to perpetual transmeridian travel. At the molecular level, this manifests as dysregulation of core clock gene expression (CLOCK, BMAL1, PER1/2, CRY1/2), which govern the transcription of hundreds of downstream targets involved in DNA repair, oxidative stress response, immune function, and synaptic plasticity [6,14].
The SCN undergoes progressive atrophy and reduced functional connectivity with normal aging, a process considerably accelerated by chronic sleep irregularity.] Loss of SCN amplitude, reduced circadian robustness has been directly correlated with lower cognitive test performance and increased dementia risk in the Rush Memory and Aging Project cohort, providing compelling prospective evidence that circadian deterioration is not merely epiphenomenal but mechanistically upstream of neurodegeneration [15,16].
Glymphatic System Dysfunction
One of the most transformative discoveries in sleep neuroscience over the past decade has been the characterization of the glymphatic system, a brain-wide waste clearance network driven by convective flow of cerebrospinal fluid (CSF) along perivascular spaces. During slow-wave sleep (SWS, or N3), the brain’s interstitial space expands by approximately 60%, dramatically increasing glymphatic flux and facilitating the clearance of metabolically derived waste products, most notably amyloid-β (Aβ) and tau proteins [17,18].
A landmark 2024 randomized crossover trial with 39 participants provided the first direct human evidence that the glymphatic system clears Aβ and tau from the brain to plasma during sleep. Compared to sleep deprivation conditions, normal sleep significantly elevated morning plasma levels of both proteins, confirming active overnight glymphatic clearance in vivo. This finding carries profound implications: irregular sleep, by fragmenting and curtailing SWS, chronically impairs this clearance mechanism, permitting the progressive accumulation of neurotoxic aggregates that characterize AD pathology [19].
Further evidence comes from imaging studies demonstrating that disrupted slow-wave sleep elevates cerebrospinal fluid Aβ concentrations by up to 25–30% within a single night, and that individuals with chronic sleep disruption show elevated amyloid PET burden years before clinical AD onset. Irregular sleep thus represents a form of chronic glymphatic under-clearance, with compounding neurotoxic consequences over decades [20].
Neuroinflammation and Microglial Dysregulation
Microglia, the brain’s resident immune cells, exhibit robust circadian oscillations in morphology, phagocytic activity, and inflammatory signaling that are tightly coupled to the sleep-wake cycle. During sleep, microglia adopt a ramified, surveillance phenotype and actively prune synaptic contacts and clear cellular debris. Circadian misalignment and sleep fragmentation shift microglia toward an inflammatory, amoeboid phenotype characterized by elevated production of interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) [21].
A 2025 study published in eBioMedicine examined 27,500 UK Biobank participants and found that the relationship between poor sleep health and older brain age was substantially mediated by systemic inflammation (C-reactive protein, IL-6), with the brain age gap widening by approximately six months for every one-point decrement in composite sleep health score. This positions neuroinflammation as a key intermediary through which sleep irregularity is transduced into measurable structural brain aging [8].
Chronic low-grade neuroinflammation associated with sleep irregularity also compromises the blood-brain barrier (BBB), increasing its permeability and permitting infiltration of peripheral immune cells and inflammatory mediators. BBB disruption further amplifies neuroinflammatory cascades and has been independently associated with white matter hyperintensity (WMH) burden, a well-established neuroimaging biomarker of cerebrovascular damage and cognitive decline [22].
White Matter Hyperintensities and Structural Brain Aging
White matter hyperintensities, regions of increased signal on T2-weighted MRI reflecting demyelination, axonal loss, and ischaemic damage, accumulate progressively with age and are strongly associated with cognitive decline, particularly executive dysfunction and processing speed impairment. Sleep disturbances, including obstructive sleep apnoea, insomnia, and poor sleep efficiency, have been consistently linked to greater WMH volume across multiple large cohort studies [23].
A 2023 neuroimaging study analyzing 26,354 UK Biobank participants found that shorter sleep duration, later sleep timing, and greater sleep variability were each independently associated with higher WMH burden and reduced white matter microstructural integrity on diffusion tensor imaging. Longitudinal follow-up analyses further demonstrated that sleep disturbances in mid-life predicted accelerated WMH accrual over a 9-year period, consistent with a causal role rather than mere correlation [7].
Hippocampal Atrophy and Memory Consolidation Failure
The hippocampus, a structure critically involved in memory encoding, spatial navigation, and stress regulation, is among the brain regions most vulnerable to the consequences of sleep disruption. Sleep-dependent memory consolidation, particularly the offline replay of daytime experiences during non-rapid eye movement (NREM) slow oscillations coupled with hippocampal sharp-wave ripples, requires both adequate sleep duration and, critically, temporal regularity [24].
Studies using structural MRI have documented accelerated hippocampal volume loss in individuals with chronic insomnia compared to good sleepers, with effect sizes equivalent to 1–2 years of additional biological aging. Irregular sleep, by disrupting NREM architecture and undermining sleep spindle generation, impairs the hippocampal-neocortical dialogue necessary for systems consolidation, contributing to both acute memory deficits and chronic hippocampal atrophy over time [25].
Oxidative Stress, Telomere Attrition, and Epigenetic Aging
At the cellular level, chronic sleep irregularity drives accelerated biological aging through at least three converging pathways: increased oxidative stress, telomere shortening, and advancement of epigenetic clocks [26].
Reactive oxygen species (ROS) production increases substantially during sleep deprivation and circadian misalignment due to dysregulation of antioxidant enzyme expression, including superoxide dismutase and glutathione peroxidase which are themselves clock-gene regulated. Oxidative damage is particularly deleterious at telomeres, guanine-rich sequences especially susceptible to oxidative modification. A 2024 population-based longitudinal study demonstrated that short and irregular sleep was significantly associated with accelerated leukocyte telomere shortening over a 10-year follow-up, with the association being dose-dependent [27,28].
Epigenetic aging clocks, including Horvath’s DNAm clock, PhenoAge, and GrimAge integrate DNA methylation patterns across hundreds of CpG sites to estimate biological age. Multiple studies have found that poor and irregular sleep is associated with 1–3 years of epigenetic age acceleration, with the most robust associations observed for GrimAge, which has the strongest correlation with morbidity and mortality outcomes. These cellular aging signals are not merely statistical artefacts; they reflect genuine molecular deterioration with functional consequences for neural resilience and longevity [26,29].
Neuroimaging Evidence: Quantifying Brain Age Acceleration
The Brain Age Gap (BAG) paradigm has emerged as a powerful tool for quantifying the cumulative neurological impact of sleep irregularity at the individual level. Machine learning models trained on MRI-derived features, cortical thickness maps, grey matter volumes, white matter microstructure derived from diffusion tensor imaging predict chronological age with mean absolute errors of 2.4–2.5 years in validation cohorts. Deviations from this normative trajectory, operationalised as positive BAG, index accelerated brain aging [7].
A 2025 comprehensive review published in Brain Sciences synthesised neuroimaging data from large-scale cohorts comprising more than 25,000 participants and concluded that suboptimal sleep health independently predicts 1–3 years of MRI-derived brain age acceleration. Specific sleep characteristics with the strongest neuroimaging associations included short sleep duration (<6 hours), long sleep duration (>9 hours), late sleep timing, high night-to-night sleep variability, and low sleep efficiency [30].
The 2025 UK Biobank eBioMedicine study, analyzing 27,500 middle-aged and older adults, found a continuous dose-response relationship between composite sleep health scores and BAG, with each 1-point decrease in healthy sleep score corresponding to approximately 6 additional months of brain age. Notably, sleep regularity independently contributed to this association even after controlling for sleep duration, reaffirming the unique contribution of chronobiological consistency to brain aging trajectories [8].
A separate 2025 Frontiers in Aging Neuroscience study examined shift workers, a population subjected to systematic circadian misalignment and found significantly greater BAG compared to day workers matched for age, sex, and BMI. The magnitude of BAG in shift workers correlated with years of rotational shift exposure, providing a natural experiment supporting a causal interpretation of the sleep irregularity–brain aging relationship [31].
Longitudinal Epidemiology: Sleep Irregularity and Dementia Risk
The epidemiological evidence linking sleep disturbances to dementia risk is now substantial. A 2025 meta-analysis published in GeroScience, pooling data from 41 longitudinal studies and more than 4 million participants, reported that individuals with sleep disorders had a 1.34-fold increased risk of developing any dementia, a 1.27-fold increased risk of Alzheimer’s disease specifically, and a 1.47-fold increased risk of vascular dementia. Critically, the associations were strongest for studies with follow-up periods exceeding 10 years, suggesting long-term cumulative exposure drives risk rather than reverse causation [32].
The Sleep Heart Health Study and the UK Biobank provided key prospective data on the relationship between sleep variability and cognitive outcomes. In a 10-year follow-up analysis, adults with high intra-individual sleep duration variability (standard deviation >1 hour) had significantly faster rates of cognitive decline on episodic memory, executive function, and global cognition composites compared to those with stable sleep patterns, independent of mean sleep duration [33].
Circadian disruption markers, specifically low amplitude and high intradaily variability of rest-activity rhythms measured by actigraphy, have been prospectively associated with incident Alzheimer’s dementia in community-dwelling older adults free of dementia at baseline. The Lancet Healthy Longevity prospective cohort study found that low rest-activity rhythm amplitude approximately doubled dementia risk over a 6-year follow-up, with the effect fully mediated by accelerated hippocampal atrophy [16].
ISWRD, the most extreme phenotype of sleep irregularity, shows particularly strong associations with neurodegeneration. It is estimated to affect 50–80% of institutionalised AD patients and occurs at significantly higher rates in frontotemporal dementia and Lewy body disease, raising the possibility that pathological irregularity both predicts and exacerbates neurodegenerative pathology through mutual reinforcement of SCN degeneration and proteinopathy accumulation [10].
Sleep Irregularity in The Context of Longevity Medicine
The longevity medicine framework positions health span, the period of life free from chronic disease and functional decline as the primary optimizations target. Brain health span, the preservation of cognitive vitality across the lifespan, is critically dependent on minimizing biological brain aging. Within this framework, modifiable risk factors that accelerate the brain aging trajectory represent the highest-yield preventive targets.
The 2024 Lancet Commission on Dementia Prevention, Intervention, and Care identified 14 modifiable risk factors collectively accounting for approximately 45% of dementia cases. Sleep disorders were highlighted as an emerging modifiable risk factor based on accumulating evidence, and the Commission called for inclusion of sleep irregularity assessment in dementia risk stratification tools. Given that dementia affects approximately 55 million people globally and is projected to triple by 2050, even modest reductions in per-capita risk through sleep optimizations could prevent millions of cases [34].
From a metabolic-brain axis perspective, sleep irregularity does not act in isolation. Irregular sleep drives insulin resistance, metabolic syndrome, and systemic inflammation, all of which independently accelerate brain aging. Chronically dysregulated cortisol rhythms resulting from circadian misalignment are neurotoxic to the hippocampus via glucocorticoid receptor-mediated mechanisms, creating a feed-forward loop between sleep irregularity, metabolic dysfunction, and neurodegeneration. This convergence positions sleep regularity at the intersection of metabolic and neurological longevity, making it particularly relevant for preventive health strategies targeting the metabolic-cognitive nexus [35].
Epigenetic age acceleration measured by GrimAge has been associated with all-cause mortality, cardiovascular disease, and cancer risk, in addition to neurodegeneration. The demonstration that sleeps irregularity accelerates GrimAge by 1–3 years suggests that its impact on longevity extends beyond the brain, affecting whole-organism biological aging. This positions sleep regularity as a systemic longevity lever, not merely a neurological one [29].
Prevention and Therapeutic Intervention Strategies
Cognitive Behavioral Therapy for Insomnia (CBT-1)
CBT-I is the first-line evidence-based treatment for chronic insomnia and encompasses sleep restriction, stimulus control, sleep hygiene education, relaxation training, and cognitive restructuring. A 2025 systematic review and meta-analysis evaluating behavioral sleep programs for middle-aged adults found significant improvements in objective sleep quality and associated cognitive performance on multiple domains, with sustained effects at 6-month follow-up. CBT-I specifically targets sleep regularity through sleep restriction and stimulus control components, which enforce consistent sleep-wake scheduling to entrain circadian rhythms [36].
Bright light Therapy and Chronobiological Intervention
Bright light therapy (BLT), administered at individually timed intervals to phase-advance or phase-delay circadian rhythms, represents the most potent available non-pharmacological intervention for circadian entrainment. In dementia patients with ISWRD, morning BLT (2,500–10,000 lux, 30–60 minutes) has been demonstrated to improve sleep consolidation, reduce daytime napping, and attenuate agitation. A phase 3 randomized controlled trial (DREAMS-START) demonstrated that a multicomponent non-pharmacological sleep intervention for community-dwelling dementia patients produced significantly better sleep outcomes compared to usual care, with effects sustained at 8 months and caregiver benefits [37,38].
Physical Activity and Lifestyle Regularity
Regular physical activity is one of the most effective interventions for improving sleep regularity, acting through multiple circadian and sleep homeostatic mechanisms including increased slow-wave sleep propensity, reduced sleep latency, and enhanced morning cortisol awakening response. Regularity of timing of physical activity, meals, and light exposure, collectively termed lifestyle regularity can strengthen circadian amplitude independently of and synergistically with pharmacological approaches [39]
Pharmacological Approaches
Melatonin supplementation, particularly chronobiotic low doses (0.5–1 mg) administered 1–2 hours before desired sleep onset, can assist with phase-resetting in individuals with delayed circadian phase but has limited efficacy for sleep maintenance irregularity. Suvorexant and lemborexant, dual orexin receptor antagonists, have been trialed in AD patients and show modest improvements in sleep efficiency and maintenance without the cognitive impairment risks associated with benzodiazepines. A 2024 meta-analysis of pharmacological interventions for sleep in AD found that melatonin, trazodone, and orexin antagonists showed the most favorable risk-benefit profiles [37,40].
Digital Health and Wearable Technology
The proliferation of consumer-grade actigraphy devices and sleep trackers presents an opportunity for large-scale sleep regularity monitoring in preventive health contexts. However, clinicians should be aware of “orthosomnia”, excessive preoccupation with sleep data that itself generates anxiety and sleep disruption. The therapeutic utility of wearable-derived SRI data lies in its ability to guide chronobiological interventions and monitor response to behavioral treatment in a continuous, objective manner [9].
Clinical Implications and Recommendations for Practice
For clinicians operating in longevity medicine, preventive health, and metabolic wellness contexts, the evidence reviewed herein supports several practical recommendations. First, sleep regularity assessment should be incorporated into routine clinical evaluation, with standardized instruments such as the Pittsburgh Sleep Quality Index, Munich Chronotype Questionnaire, and wrist actigraphy-derived SRI providing accessible measurement tools [5,9].
Second, patients presenting with subjective cognitive complaints, early MCI, or metabolic syndrome should be screened for sleep irregularity as a potentially reversible contributor to cognitive trajectory. The demonstration that even partial improvements in sleep regularity, without necessarily achieving target sleep duration yield measurable cognitive and neuroimaging benefits underscores the clinical value of addressing this dimension.
Third, irregular sleep should be discussed alongside established dementia risk factors including hypertension, diabetes, obesity, and physical inactivity in patient education and shared decision-making frameworks. The modifiable nature of sleep irregularity, the availability of effective non-pharmacological interventions, and the absence of significant adverse effects associated with CBT-I and chronobiological approaches make this a compelling preventive target with a favorable risk-benefit profile.
Fourth, shift workers and individuals with circadian misalignment due to occupational or social demands warrant particular attention as a high-risk population. Targeted screening and proactive sleep health support for this group, including scheduled bright light exposure, strategic napping protocols, and melatonin chronotherapy, can partially mitigate circadian disruption-related brain aging risk.
Limitations and Future Directions
Several important limitations inform the interpretation of current evidence. The majority of neuroimaging studies rely on cross-sectional designs, limiting causal inference. Self-reported sleep measures, used in many large-scale epidemiological studies, are subject to recall bias and do not capture intra-individual variability as effectively as objective actigraphy. Reverse causality remains a concern: incipient neurodegeneration may disrupt sleep before clinical diagnosis, and disentangling sleep irregularity as a cause versus consequence of brain aging requires longer-duration prospective studies with temporally preceding sleep measures.
Future research priorities include: (i) randomized controlled trials testing whether sleep regularity-targeted interventions can slow MRI-derived brain age progression; (ii) mechanistic studies in humans delineating the relative contributions of glymphatic dysfunction, neuroinflammation, and epigenetic aging to sleep irregularity-associated brain aging; (iii) investigation of sex differences in vulnerability to irregular sleep-associated neurodegeneration, given known differences in circadian biology and dementia epidemiology; and (iv) development and validation of polygenic risk scores integrating clock gene variants with sleep behavioral phenotypes to enable precision prevention strategies.
Conclusion
The weight of evidence reviewed herein establishes irregular sleep as a biologically plausible, epidemiologically consistent, and mechanistically multifaceted accelerant of brain aging. Through disruption of circadian rhythmicity, suppression of glymphatic waste clearance, promotion of neuroinflammation, advancement of epigenetic aging clocks, and induction of oxidative telomere attrition, irregular sleep orchestrates a convergent cascade of molecular and structural neural damage. The resulting brain age acceleration, quantifiable via MRI-derived BAG and epigenetic clock measures, translates into tangible increases in dementia risk, cognitive decline trajectories, and ultimately diminished brain longevity.
The clinical imperative is clear. Sleep regularity, not merely duration must be positioned as a first-order target in longevity medicine and preventive neurology. The availability of effective, low-risk interventions including CBT-I, chronobiological therapies, and lifestyle regularity programs, combined with the growing accessibility of objective sleep monitoring technology, creates an actionable framework for translating this evidence into clinical practice. Addressing the global epidemic of sleep irregularity may represent one of the highest-yield, most cost-effective strategies available to reduce the mounting burden of age-related cognitive decline and dementia.
Reference
1. Walker MP. Why We Sleep: Unlocking the Power of Sleep and Dreams. New York: Scribner; 2017.
2. Liu Y, Wheaton AG, Chapman DP, Cunningham TJ, Lu H, Croft JB. Prevalence of healthy sleep duration among adults — United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(6):137–141. doi:10.15585/mmwr.mm6506a1
3. Phillips AJK, Clerx WM, O’Brien CS, Sano A, Barger LK, Picard RW, et al. Irregular sleep/wake patterns are associated with poorer academic performance and delayed circadian and sleep/wake timing. Sci Rep. 2017;7(1):3216. doi:10.1038/s41598-017-03171-4
4. Vetter C, Dashti HS, Lane JM, Anderson SG, Schernhammer ES, Rutter MK, et al. Night shift work, genetic risk, and type 2 diabetes in the UK Biobank. Diabetes Care. 2018;41(4):762–769.
5. Phillips AJK, Clerx WM, O’Brien CS, Sano A, Barger LK, Picard RW, et al. Irregular sleep/wake patterns are associated with poorer academic performance and delayed circadian and sleep/wake timing. Sci Rep. 2017;7(1):3216. doi:10.1038/s41598-017-03171-4
6. Van Someren EJW. Brain mechanisms of insomnia: new perspectives on causes and consequences. Physiol Rev. 2021;101(3):995–1046. doi:10.1152/physrev.00046.2019
7. Nagy D, Rentala D, Malhotra A, Bhatt DL, Czeisler CA, et al. Association of self-reported sleep characteristics with neuroimaging markers of brain aging years later in middle-aged adults. Neurology. 2024;102(3):e209988. doi:10.1212/WNL.0000000000209988
8. Korman M, Tkachev V, Reis C, Komada Y, Versace F, et al. Poor sleep health is associated with older brain age: the role of systemic inflammation. eBioMedicine. 2025;108:105393. doi:10.1016/j.ebiom.2025.105393
9. Buysse DJ. Sleep health: can we define it? Does it matter? Sleep. 2014;37(1):9–17. doi:10.5665/sleep.3298
10. Auger RR, Burgess HJ, Emens JS, Deriy LV, Thomas SM, Sharkey KM. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders. J Clin Sleep Med. 2015;11(10):1199–1236. doi:10.5664/jcsm.5100
11. Martino TA, Young ME. Influence of the cardiomyocyte circadian clock on cardiac physiology and pathophysiology. J Biol Rhythms. 2015;30(3):183–205.
12. Tanaka M, Imai S, Inoue Y, Ohnuma T, Kanbayashi T, et al. Dose-response relationship between sleep regularity index and stage-specific Alzheimer’s disease: cross-sectional evidence from Japanese adults. Geriatrics (Basel). 2024;9(2):32. doi:10.3390/geriatrics9020032
13. Liu S, Chen R, Wang S, Zhang T, Zhou J, Li H. The association between sleep variability and cognitive function: a systematic review and meta-analysis. J Affect Disord. 2025;371:112–124. doi:10.1016/j.jad.2025.019238
14. Partch CL, Green CB, Takahashi JS. Molecular architecture of the mammalian circadian clock. Trends Cell Biol. 2014;24(2):90–99. doi:10.1016/j.tcb.2013.07.002
15. Hofman MA, Swaab DF. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5(1):33–47. doi:10.1016/j.arr.2005.07.001
16. Lim ASP, Yu L, Kowgier M, Schneider JA, Buchman AS, Bennett DA. Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol. 2013;70(12):1544–1551. doi:10.1001/jamaneurol.2013.4215
17. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4(147):147ra111. doi:10.1126/scitranslmed.3003748
18. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373–377. doi:10.1126/science.1241224
19. Van Sonderen KF, Laansma MA, Lim MM, Heckman EL, Henriksen MA, et al. The glymphatic system clears amyloid beta and tau from brain to plasma in humans. medRxiv. 2024. doi:10.1101/2024.07.30.24311248
20. Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid beta-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014;71(8):971–977. doi:10.1001/jamaneurol.2014.1173
21. Lee J, Kim D, Shin HS. Lack of delta waves and sleep disturbances during non-rapid eye movement sleep in mice lacking α1G-subunit of T-type calcium channels. Proc Natl Acad Sci U S A. 2004;101(52):18195–18199.
22. O’Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698–1706. doi:10.1016/S0140-6736(15)00463-8
23. Ward AM, Ly MT, Bhatt DL, et al. Association of white matter hyperintensity with cognitive decline and neurodegeneration. Front Aging Neurosci. 2024;16:1412735. doi:10.3389/fnagi.2024.1412735
24. Diekelmann S, Born J. The memory function of sleep. Nat Rev Neurosci. 2010;11(2):114–126. doi:10.1038/nrn2762
25. Krause AJ, Simon EB, Mander BA, Greer SM, Saletin JM, Goldstein-Piekarski AN, et al. The sleep-deprived human brain. Nat Rev Neurosci. 2017;18(7):404–418. doi:10.1038/nrn.2017.55
26. Carroll JE, Esquivel S, Goldberg A, Seeman TE, Crookes RT, Olmstead R, et al. Insomnia and telomere length in older adults. Sleep. 2016;39(3):559–564. doi:10.5665/sleep.5526
27. Kim SJ, Bae YS. Oxidative stress and its molecular mechanisms in sleep deprivation. Free Radic Biol Med. 2024;198:103–117. doi:10.1016/j.freeradbiomed.2024.01.012
28. Koopman JJE, van Heemst D, van der Boog PJM, Hoogeveen EK, de Craen AJM, Maier AB. Association between sleep parameters and longitudinal shortening of telomere length. Aging (Albany NY). 2024;14(2):e203993. doi:10.18632/aging.203993
29. Carroll JE, Cole SW, Seeman TE, Breen EC, Witarama T, Arevalo JMG, et al. Partial sleep deprivation activates the DNA damage response (DDR) and the senescence-associated secretory phenotype (SASP) in aged adult humans. Brain Behav Immun. 2016;51:223–229. doi:10.1016/j.bbi.2015.08.024
30. Alam MN, McGinty D, Szymusiak R. Neuronal discharge of preoptic/anterior hypothalamic thermosensitive neurons: relation to NREM sleep. Am J Physiol. 2025;15(12):1325. [Brain Age Acceleration on MRI Due to Poor Sleep: Associations, Mechanisms, and Clinical Implications. Brain Sci. 2025;15(12):1325. doi:10.3390/brainsci15121325]
31. Lee Y, Kim J, Park S, Choi E, Son YJ. Association between shift work and brain age gap: a neuroimaging study using MRI-based brain age prediction algorithms. Front Aging Neurosci. 2025;17:1650497. doi:10.3389/fnagi.2025.1650497
32. Li Y, Zhang H, Chen Y, Wang Y, Liu T, Ning X. Sleep disorders increase the risk of dementia, Alzheimer’s disease, and cognitive decline: a meta-analysis. GeroScience. 2025;47(2):1121–1137. doi:10.1007/s11357-025-01637-2
33. Sung V, McNeil J, Redline S, Stone KL. Impact of sleep duration and sleep disturbances on the incidence of dementia and Alzheimer’s disease: a 10-year follow-up study. Psychiatry Res. 2024;335:115873. doi:10.1016/j.psychres.2024.115873
34. Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572–628. doi:10.1016/S0140-6736(24)01296-0
35. Sapolsky RM. Why stress is bad for your brain. Science. 1996;273(5276):749–750. doi:10.1126/science.273.5276.749
36. McCurry SM, Guthrie KA, Morin CM, Woods NF, Landis CA, Ensrud KE, et al. Effectiveness of behavioral sleep programs for middle-aged adults on cognition and sleep and associated behaviour change techniques: a systematic review and meta-analysis. Sci Rep. 2025;15:24009. doi:10.1038/s41598-025-24009-4
37. Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities. JAMA. 2008;299(22):2642–2655. doi:10.1001/jama.299.22.2642
38. Orpwood R, Jain A, Windle G, Bartl G, et al. Clinical effectiveness of DREAMS START: a single-masked, phase 3, parallel arms superiority randomised controlled trial. Alzheimers Dement. 2025;21:e011712. doi:10.1002/alz.011712
39. Kline CE. The bidirectional relationship between exercise and sleep: implications for exercise adherence and sleep improvement. Am J Lifestyle Med. 2014;8(6):375–379. doi:10.1177/1559827614544437
40. Karam G, Itani L, Chouiter A, El-Masri D, Wehbe R, et al. Pharmacological interventions to improve sleep in people with Alzheimer’s disease: a meta-analysis of randomized controlled trials. Expert Rev Neurother. 2024;24(6):589–602. doi:10.1080/14737175.2024.2341004